Turnaround bets placed by Axovant Sciences Ltd. on early stage gene therapies in the wake of its failed bid to tackle Alzheimer's disease (AD) showed hints of paying off, boosting company shares (NASDAQ:AXGT) by 14.2 percent to $1.69 on Monday. Positive interim results from two patients in a phase II study of AXO-Lenti-PD in Parkinson's disease (PD) and initial data on its Tay-Sachs disease candidate, AXO-AAV-GM2, put both programs on track for further development.